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Fluconazole remains in routine use as an induction regimen for the treatment of 
Cryptococcal meningitis (CM) in many low and middle income countries (LMICs), 
either alone, or in combination with amphotericin B. Guidelines recommend 
dosages of 800mg/day to 1200mg/day [1-3]. However, it has been previously 
suggested that fluconazole may prolong the QT interval, either directly, or by 
inhibiting the hepatic metabolism of other QT-prolonging agents [4, 5].  A 
lengthened corrected QT interval (QTc) is a biomarker for ventricular 
tachyarrhythmias such as torsades de pointes and is a risk factor for sudden death, 
particularly in older patients [6]. In a prior study of CM, patients receiving 
amphotericin B plus fluconazole (800mg/day) had a slight increase in QTc 
compared with baseline (mean change from baseline: 6.6ms [95%CI: -3.2ms to 
16.4ms]) [4].  However, overall, day 7 QTc intervals for those treated with 
amphotericin B plus fluconazole (800mg/day) were similar compared with 
patients treated with amphotericin B in combination with fluconazole, at the 
lower dose of 400mg/day, and amphotericin B alone; and there was no suggestion 
of an increase in the risk of clinically significant QTc prolongation (>500ms) [4].  
We assessed the effect of a fluconazole dose of 1200mg/day, on QTc interval in a 
cohort of patients enrolled in the ACTA trial. This was a Phase III trial for the 
treatment of HIV-associated CM in Africa testing 5 different treatment regimens, 
3 of which contained fluconazole at 1200mg/day dosage [7]. Electrocardiograms 
(ECGs) to measure the heart rate corrected QT (QTc – using Bazett’s formula) were 
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performed for all participants at baseline and 1 week after enrolment, for the first 
22 months of the study, until the Data Monitoring Committee recommended to 
discontinue routine ECG monitoring on the basis that the clinical risk did not 
warrant routine ECG monitoring in this context.  
 
QTc results from patients randomised to regimens including fluconazole, 
1200mg/day (oral treatment of fluconazole plus flucytosine for 2 weeks; 
amphotericin B plus fluconazole for 1 week, and amphotericin B plus fluconazole 
for 2 weeks, 2/3 of those enrolled in the trial) were compared to those randomised 
to non-fluconazole containing regimens (amphotericin B plus flucytosine for 1 
week and amphotericin B plus flucytosine for 2 weeks, 1/3 of those enrolled). 
Mean QTc length in each of the 2 groups at day 7 was compared by analysis of 
covariance (ANCOVA), adjusting for baseline QTc measurement. Mean change in 
QTc length from baseline to day 7 was analysed using a t-test and the proportion 
of patients with long QTc (≥500ms) in each group was compared at day 7 using 
Fishers exact test. Analyses were performed using Stata version 14.1.  
 
A total of 150 patients had QTc results recorded at baseline with 104 (69.33%) 
randomised to a high dose fluconazole treatment regimen. As expected there was 
no significant difference in mean QTc length for patients randomized to 
fluconazole treatment compared to those randomised to no fluconazole at 
baseline (412.9ms and 414.2ms, respectively, p=0.88). At baseline, 15 patients 
(10%) had Grade 1 (450-480ms), 6 patients (4%) had Grade 2 (480-490ms) and 
7 patients (4.67%) had Grade 3 QTc (>500ms) at baseline. Of the patients with 
Grade 3 QTc at baseline, 6 resolved (<450ms) by day 7 with electrolyte 
replacement and avoidance of known QT prolonging concomitant drugs. 
Fluconazole was withheld temporarily for 2 patients. One patient with severe CM 
and sepsis died prior to a follow-up ECG. 
 
Following commencement of antifungal treatment, QTc was recorded for 125 
patients at day 7 with 84 (67.2%) randomised to high dose fluconazole.  Sixteen 
patients (12.8%) had Grade 1 (450-480ms), 8 patients (6.4%) had a Grade 2 (480-
490ms) and 1 patient (0.8%) had a Grade 3 QTc (>500ms) at day 7. The patient 
with Grade 3 QTc had a normal QTc at baseline (437ms) that increased at day 7 to 
505ms and this patient was randomised to a fluconazole containing treatment 
regimen. The patient was well on discharge at day 14 of the study and completed 
10-week follow-up without further adverse events. Overall mean QTc length at 
day 7 was 415.8ms (IQR: 390.0 to 444.0). The mean change in QTc length from 
baseline was 2.9ms (IQR: -30 to 37):  10.1ms (IQR: -28 to 46) in the fluconazole 
containing treatment group compared to -12.6ms (IQR: -39 to 13.5) in those not 
taking fluconazole (p=0.04) (Table 1). There was evidence for a difference in mean 
QTc length for patients taking fluconazole treatment compared to those not taking 
fluconazole (422.5ms and 402.1ms, respectively, p=0.01), adjusting for baseline 
QTc length. However, there was no evidence for a difference in the number of 
patients with long QTc (>500ms) between the 2 groups at day 7 (1 patient had a 
long QTc in the fluconazole group compared to none in the non-fluconazole group, 
p=1.0) (Table 1). 
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 A small increase in mean QTc length for patients taking high dose fluconazole 
(1200mg/day) was observed in this study, as shown previously for doses of 
800mg/day [4]. As in the prior study, there was no evidence for an increase in the 
proportion of patients developing a clinically significant prolonged QT interval. 
Since our study was conducted, preliminary results of a phase II trial using even 
higher fluconazole doses (1600mg/day and 2000mg/day) have been reported, 
without, as yet, details of QT interval effects but with no mention of serious 
concerns over QT interval prolongation [8]. 
 
Our study suggests that a fluconazole dose of 1200mg/day does not lead to 
clinically significant lengthening of the QTc interval and that ECG monitoring need 
not be mandatory in this population, treated at this dose for short periods. 
However, it is important to emphasize, as with all drugs with the potential to 
prolong QT interval, that it remains important to monitor and correct any 
electrolyte imbalance and to avoid, where possible, concomitant drugs that may 
also raise QTc prolongation. 
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Table 1: QTc measurements at baseline and Day 7 by treatment group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 ANCOVA analysis adjusting for baseline QTc  
2 Fishers exact test 
3 t-test 
 
 
  
Day 7  
   (n=113)                       (n=125)   
Mean change from 
baseline to day 7 
(n=113) 
Treatment 
group 
 Mean QTc, ms  
(IQR) 
Long QTc, ms 
n (%) 
Mean change, ms   
(IQR) 
Fluconazole   422.5 (401 to 448.5) 1 (1.0%) 10.1 (-28 to 46) 
No fluconazole  402.1 (385 to 443) 0 -12.6 (-39 to 13.5) 
p-value  0.011 1.02 0.043 
Overall   415.8 (390.0 to 
440.0) 
1 (0.8%) 2.9 (-30 to 37) 
